{"id":273,"date":"2026-11-08T16:04:04","date_gmt":"2026-11-08T05:04:04","guid":{"rendered":"https:\/\/pressuraneuro.com\/newsite\/?page_id=273"},"modified":"2026-11-20T11:25:46","modified_gmt":"2026-11-20T00:25:46","slug":"development-programme","status":"publish","type":"page","link":"https:\/\/pressuraneuro.com\/newsite\/development-programme\/","title":{"rendered":"Development Programme"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; module_class=&#8221;pn-development-title&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; border_color_all=&#8221;gcid-6d5e15e2-bc98-4253-aa71-4c19bf47ea9f&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{%22gcid-6d5e15e2-bc98-4253-aa71-4c19bf47ea9f%22:%91%22background_color%22,%22border_color_all%22%93}&#8221;][et_pb_row _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1>Development Programme<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_class=&#8221;pn-development-main&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#ffffff&#8221; custom_padding=&#8221;50px||12px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_row column_structure=&#8221;1_3,2_3&#8243; module_class=&#8221;pn-development-intro-row&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;0px||20px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_2_font=&#8221;Inter||||||||&#8221; header_2_text_color=&#8221;#071240&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.15em&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; header_2_text_align_tablet=&#8221;&#8221; header_2_text_align_phone=&#8221;center&#8221; header_2_text_align_last_edited=&#8221;on|phone&#8221; header_2_text_color_tablet=&#8221;#071240&#8243; header_2_text_color_phone=&#8221;#071240&#8243; header_2_text_color_last_edited=&#8221;on|desktop&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<h2>Introduction.<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#071240&#8243; text_font_size=&#8221;15px&#8221; text_line_height=&#8221;1.65em&#8221; text_orientation_tablet=&#8221;&#8221; text_orientation_phone=&#8221;center&#8221; text_orientation_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p>PresSura is developing a single compound, EU-C-001, across a number of neurological conditions in which a rise in intracranial pressure and other proteins plays a central role.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_5,2_5,2_5&#8243; module_class=&#8221;pn-development-condition-row&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;28px||28px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#d8e0ee&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/moderate-to-severe-traumatic-brain-injury@3x.png&#8221; title_text=&#8221;moderate-to-severe-traumatic-brain-injury@3x&#8221; force_fullwidth=&#8221;on&#8221; module_class=&#8221;pn-development-condition-image&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text module_class=&#8221;pn-development-condition-heading&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#071240&#8243; header_3_font_size=&#8221;28px&#8221; header_3_line_height=&#8221;1.15em&#8221; header_3_text_align_tablet=&#8221;&#8221; header_3_text_align_phone=&#8221;center&#8221; header_3_text_align_last_edited=&#8221;on|phone&#8221; text_orientation_tablet=&#8221;&#8221; text_orientation_phone=&#8221;center&#8221; text_orientation_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<h3>Moderate to Severe<br \/>Traumatic Brain Injury<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#071240&#8243; text_font_size=&#8221;15px&#8221; text_line_height=&#8221;1.65em&#8221; text_orientation_tablet=&#8221;&#8221; text_orientation_phone=&#8221;center&#8221; text_orientation_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p>EU-C-001 is in a Phase 2A double-blind trial in moderate to severe TBI across multiple countries. The trial has completed enrolment and follows a Phase 1 programme and an open-label phase.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_5,2_5,2_5&#8243; module_class=&#8221;pn-development-condition-row&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;28px||28px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#d8e0ee&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/stroke-and-other-neurological-conditions.png&#8221; force_fullwidth=&#8221;on&#8221; module_class=&#8221;pn-development-condition-image&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text module_class=&#8221;pn-development-condition-heading&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#071240&#8243; header_3_font_size=&#8221;28px&#8221; header_3_line_height=&#8221;1.15em&#8221; header_3_text_align_tablet=&#8221;&#8221; header_3_text_align_phone=&#8221;center&#8221; header_3_text_align_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<h3>Stroke and Other<br \/>Neurological Conditions<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#071240&#8243; text_font_size=&#8221;15px&#8221; text_line_height=&#8221;1.65em&#8221; text_orientation_tablet=&#8221;&#8221; text_orientation_phone=&#8221;center&#8221; text_orientation_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p>PresSura is targetting stroke as a leading indication in its development program. A preclinical primary pharmacology programme has been completed and a full Phase 1 safety data package in healthy volunteers is available. Plans for a Phase 2A Proof of Concept study are in development.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_5,2_5,2_5&#8243; module_class=&#8221;pn-development-condition-row&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;28px||28px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#d8e0ee&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/concussion-related-conditions@3x.png&#8221; title_text=&#8221;concussion-related-conditions@3x&#8221; force_fullwidth=&#8221;on&#8221; module_class=&#8221;pn-development-condition-image&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text module_class=&#8221;pn-development-condition-heading&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#071240&#8243; header_3_font_size=&#8221;28px&#8221; header_3_line_height=&#8221;1.15em&#8221; header_3_text_align_tablet=&#8221;&#8221; header_3_text_align_phone=&#8221;center&#8221; header_3_text_align_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<h3>Concussion Related<br \/>Conditions<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#071240&#8243; text_font_size=&#8221;15px&#8221; text_line_height=&#8221;1.65em&#8221; text_orientation_tablet=&#8221;&#8221; text_orientation_phone=&#8221;center&#8221; text_orientation_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p>PresSura is targeting mild TBI (concussion) building on its current moderate to severe TBI trial. A focussed preclinical primary pharmacology programme in concussion and a Phase 1 in healthy volunteers are complete; a Phase 2A programme in mTBI is being planned.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; disabled_on=&#8221;on|on|off&#8221; admin_label=&#8221;Desktop Chart&#8221; module_class=&#8221;pn-development-portfolio&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#ffffff&#8221; custom_padding=&#8221;20px||35px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_row _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;0px||10px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_2_font=&#8221;Inter||||||||&#8221; header_2_text_color=&#8221;#071240&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.15em&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<h2>Portfolio.<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,1_4,1_4,1_4&#8243; module_class=&#8221;pn-development-stage-header&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#071240&#8243; custom_padding=&#8221;10px|4px|10px|4px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"text-align:center;color:#ffffff;font-size:12px;letter-spacing:.04em\">PRECLINICAL<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#071240&#8243; custom_padding=&#8221;10px|4px|10px|4px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"text-align:center;color:#ffffff;font-size:12px;letter-spacing:.04em\">PHASE 1<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#071240&#8243; custom_padding=&#8221;10px|4px|10px|4px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"text-align: center; color: #ffffff; font-size: 12px; letter-spacing: .04em;\">PHASE 2A<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#071240&#8243; custom_padding=&#8221;10px|4px|10px|4px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"text-align:center;color:#ffffff;font-size:12px;letter-spacing:.04em\">PHASE 3<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; module_class=&#8221;pn-development-portfolio-row&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#e5edff&#8221; custom_padding=&#8221;12px|8px|12px|8px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"text-align:center;font-size:14px;color:#071240\">Moderate\/severe TBI<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text module_class=&#8221;pn-development-stage-bar&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; background_color=&#8221;#2860f0&#8243; width=&#8221;74%&#8221; custom_padding=&#8221;12px|12px|12px|12px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"font-size: 13px; color: #fff;\">Phase 2A \u2013 PANGEA Study<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; module_class=&#8221;pn-development-portfolio-row&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#e5edff&#8221; custom_padding=&#8221;12px|8px|12px|8px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"text-align:center;font-size:14px;color:#071240\">Stroke<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text module_class=&#8221;pn-development-stage-bar&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#88aff9&#8243; width=&#8221;49%&#8221; custom_padding=&#8221;12px|12px|12px|12px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"font-size:13px;color:#071240\">Phase 1 Completed<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; module_class=&#8221;pn-development-portfolio-row&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#e5edff&#8221; custom_padding=&#8221;12px|8px|12px|8px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"text-align:center;font-size:14px;color:#071240\">Concussion \/ PCS<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text module_class=&#8221;pn-development-stage-bar&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#88aff9&#8243; width=&#8221;42%&#8221; custom_padding=&#8221;12px|12px|12px|12px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p style=\"font-size: 13px; color: #071240;\">Phase 1 Completed<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; module_class=&#8221;pn-development-ip&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#eaf0f8&#8243; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; custom_padding=&#8221;14px|16px|14px|16px|true|true&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#071240&#8243; header_3_font_size=&#8221;21px&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<h3>IP.<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#071240&#8243; text_font_size=&#8221;15px&#8221; text_line_height=&#8221;1.65em&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p>A strong IP portfolio covering the various indications, with patent life ranging from 2034 to 2040. IP managed through Davies Collison Cave, a leading international IP firm headquartered in Melbourne.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=&#8221;pn-development-decoration&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/firefly.png&#8221; module_class=&#8221;pn-development-corner-art&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; disabled_on=&#8221;off|off|on&#8221; admin_label=&#8221;MOBILE&#8221; module_class=&#8221;pn-development-portfolio&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#ffffff&#8221; custom_padding=&#8221;20px||35px||false|false&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_row _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||||false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{{}}&#8221; sticky_enabled=&#8221;0&#8243; width=&#8221;100%&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{{}}&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_2_font=&#8221;Inter||||||||&#8221; header_2_text_color=&#8221;#071240&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.15em&#8221; custom_margin=&#8221;||||false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{{}}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h2>Portfolio.<\/h2>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/severe-TBI.png&#8221; title_text=&#8221;severe TBI&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/Stroke.png&#8221; title_text=&#8221;Stroke&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/PCS.png&#8221; title_text=&#8221;PCS&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; module_class=&#8221;pn-development-ip&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#eaf0f8&#8243; custom_padding=&#8221;14px|16px|14px|16px|true|true&#8221; hover_enabled=&#8221;0&#8243; border_radii=&#8221;on|10px|10px|10px|10px&#8221; global_colors_info=&#8221;{{}}&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#071240&#8243; header_3_font_size=&#8221;21px&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<h3>IP.<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#071240&#8243; text_font_size=&#8221;15px&#8221; text_line_height=&#8221;1.65em&#8221; global_colors_info=&#8221;{{}}&#8221;]<\/p>\n<p>A strong IP portfolio covering the various indications, with patent life ranging from 2034 to 2040. IP managed through Davies Collison Cave, a leading international IP firm headquartered in Melbourne.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=&#8221;pn-development-decoration&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;86%&#8221; max_width=&#8221;1120px&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/firefly.png&#8221; module_class=&#8221;pn-development-corner-art&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{{}}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Development ProgrammeIntroduction.PresSura is developing a single compound, EU-C-001, across a number of neurological conditions in which a rise in intracranial pressure and other proteins plays a central role.Moderate to SevereTraumatic Brain InjuryEU-C-001 is in a Phase 2A double-blind trial in moderate to severe TBI across multiple countries. The trial has completed enrolment and follows a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-273","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/pages\/273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/comments?post=273"}],"version-history":[{"count":18,"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/pages\/273\/revisions"}],"predecessor-version":[{"id":499,"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/pages\/273\/revisions\/499"}],"wp:attachment":[{"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/media?parent=273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}